Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Inovio Pharmaceuticals Q2 2024 GAAP EPS $(1.19) Misses $(1.10) Estimate, Sales $100.762K Miss $121.500K Estimate

Author: Benzinga Newsdesk | August 08, 2024 04:38pm
Inovio Pharmaceuticals (NASDAQ:INO) reported quarterly losses of $(1.19) per share which missed the analyst consensus estimate of $(1.10) by 8.18 percent. The company reported quarterly sales of $100.762 thousand which missed the analyst consensus estimate of $121.500 thousand by 17.07 percent. This is a 55.41 percent decrease over sales of $225.971 thousand the same period last year.

Posted In: INO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist